These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 24266007)
1. Jacobian integration method increases the statistical power to measure gray matter atrophy in multiple sclerosis. Nakamura K; Guizard N; Fonov VS; Narayanan S; Collins DL; Arnold DL Neuroimage Clin; 2014; 4():10-7. PubMed ID: 24266007 [TBL] [Abstract][Full Text] [Related]
2. SIENA-XL for improving the assessment of gray and white matter volume changes on brain MRI. Battaglini M; Jenkinson M; De Stefano N; Hum Brain Mapp; 2018 Mar; 39(3):1063-1077. PubMed ID: 29222814 [TBL] [Abstract][Full Text] [Related]
3. Exploring the effect of glatiramer acetate on cerebral gray matter atrophy in multiple sclerosis. AbdelRazek MA; Tummala S; Khalid F; Tauhid S; Jalkh Y; Khalil S; Hurwitz S; Zurawski J; Bakshi R J Neurol Sci; 2023 Jan; 444():120501. PubMed ID: 36481574 [TBL] [Abstract][Full Text] [Related]
4. Methods for Brain Atrophy MR Quantification in Multiple Sclerosis: Application to the Multicenter INNI Dataset. Storelli L; Pagani E; Pantano P; Piervincenzi C; Tedeschi G; Gallo A; De Stefano N; Battaglini M; Rocca MA; Filippi M; J Magn Reson Imaging; 2023 Oct; 58(4):1221-1231. PubMed ID: 36661195 [TBL] [Abstract][Full Text] [Related]
5. Age-dependent cut-offs for pathological deep gray matter and thalamic volume loss using Jacobian integration. Opfer R; Krüger J; Spies L; Hamann M; Wicki CA; Kitzler HH; Gocke C; Silva D; Schippling S Neuroimage Clin; 2020; 28():102478. PubMed ID: 33269702 [TBL] [Abstract][Full Text] [Related]
6. Measurement of Whole-Brain and Gray Matter Atrophy in Multiple Sclerosis: Assessment with MR Imaging. Storelli L; Rocca MA; Pagani E; Van Hecke W; Horsfield MA; De Stefano N; Rovira A; Sastre-Garriga J; Palace J; Sima D; Smeets D; Filippi M; Radiology; 2018 Aug; 288(2):554-564. PubMed ID: 29714673 [TBL] [Abstract][Full Text] [Related]
7. Determinants of Deep Gray Matter Atrophy in Multiple Sclerosis: A Multimodal MRI Study. Pontillo G; Cocozza S; Lanzillo R; Russo C; Stasi MD; Paolella C; Vola EA; Criscuolo C; Borrelli P; Palma G; Tedeschi E; Morra VB; Elefante A; Brunetti A AJNR Am J Neuroradiol; 2019 Jan; 40(1):99-106. PubMed ID: 30573464 [TBL] [Abstract][Full Text] [Related]
8. Agreement of MSmetrix with established methods for measuring cross-sectional and longitudinal brain atrophy. Steenwijk MD; Amiri H; Schoonheim MM; de Sitter A; Barkhof F; Pouwels PJW; Vrenken H Neuroimage Clin; 2017; 15():843-853. PubMed ID: 28794970 [TBL] [Abstract][Full Text] [Related]
9. Corpus callosum atrophy correlates with gray matter atrophy in patients with multiple sclerosis. Klawiter EC; Ceccarelli A; Arora A; Jackson J; Bakshi S; Kim G; Miller J; Tauhid S; von Gizycki C; Bakshi R; Neema M J Neuroimaging; 2015; 25(1):62-7. PubMed ID: 24816394 [TBL] [Abstract][Full Text] [Related]
10. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis. Yousuf F; Dupuy SL; Tauhid S; Chu R; Kim G; Tummala S; Khalid F; Weiner HL; Chitnis T; Healy BC; Bakshi R J Neurol Sci; 2017 Dec; 383():221-229. PubMed ID: 29146095 [TBL] [Abstract][Full Text] [Related]
11. Effect of glatiramer acetate on cerebral grey matter pathology in patients with relapsing-remitting multiple sclerosis. Crescenzo F; Marastoni D; Zuco C; Pitteri M; Magliozzi R; Monaco S; Calabrese M Mult Scler Relat Disord; 2019 Jan; 27():305-311. PubMed ID: 30453199 [TBL] [Abstract][Full Text] [Related]
12. Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis. Gaetano L; Häring DA; Radue EW; Mueller-Lenke N; Thakur A; Tomic D; Kappos L; Sprenger T Neurology; 2018 Apr; 90(15):e1324-e1332. PubMed ID: 29540589 [TBL] [Abstract][Full Text] [Related]
13. Unraveling the relationship between regional gray matter atrophy and pathology in connected white matter tracts in long-standing multiple sclerosis. Steenwijk MD; Daams M; Pouwels PJ; J Balk L; Tewarie PK; Geurts JJ; Barkhof F; Vrenken H Hum Brain Mapp; 2015 May; 36(5):1796-807. PubMed ID: 25627545 [TBL] [Abstract][Full Text] [Related]
14. Disability-Specific Atlases of Gray Matter Loss in Relapsing-Remitting Multiple Sclerosis. MacKenzie-Graham A; Kurth F; Itoh Y; Wang HJ; Montag MJ; Elashoff R; Voskuhl RR JAMA Neurol; 2016 Aug; 73(8):944-53. PubMed ID: 27294295 [TBL] [Abstract][Full Text] [Related]
15. Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity. Bermel RA; Puli SR; Rudick RA; Weinstock-Guttman B; Fisher E; Munschauer FE; Bakshi R Arch Neurol; 2005 Sep; 62(9):1371-6. PubMed ID: 16157744 [TBL] [Abstract][Full Text] [Related]
16. Grey matter atrophy in patients suffering from multiple sclerosis. Kincses ZT; Tóth E; Bankó N; Veréb D; Szabó N; Csete G; Faragó P; Király A; Bencsik K; Vécsei L Ideggyogy Sz; 2014 Sep; 67(9-10):293-300. PubMed ID: 25518257 [TBL] [Abstract][Full Text] [Related]
18. Neuroprotective effects of testosterone treatment in men with multiple sclerosis. Kurth F; Luders E; Sicotte NL; Gaser C; Giesser BS; Swerdloff RS; Montag MJ; Voskuhl RR; Mackenzie-Graham A Neuroimage Clin; 2014; 4():454-60. PubMed ID: 24634831 [TBL] [Abstract][Full Text] [Related]
19. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center. Wolinsky JS; Narayana PA; Johnson KP; Mult Scler; 2001 Feb; 7(1):33-41. PubMed ID: 11321192 [TBL] [Abstract][Full Text] [Related]
20. Assessing Biological and Methodological Aspects of Brain Volume Loss in Multiple Sclerosis. Andorra M; Nakamura K; Lampert EJ; Pulido-Valdeolivas I; Zubizarreta I; Llufriu S; Martinez-Heras E; Sola-Valls N; Sepulveda M; Tercero-Uribe A; Blanco Y; Saiz A; Villoslada P; Martinez-Lapiscina EH JAMA Neurol; 2018 Oct; 75(10):1246-1255. PubMed ID: 29971335 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]